Exact claim · Version 1 · Reviewed 2026-07-23
“Abaloparatide reduced fractures in a randomized phase 3 trial.”
A verdict on this wording and scope, not a universal grade for Abaloparatide.
01 · Verdict
Supported with scope
ACTIVE found fewer new vertebral and nonvertebral fractures versus placebo in postmenopausal women with osteoporosis.
- Evidence basis
- Randomized human outcomes
- Scope
- Postmenopausal women with osteoporosis at fracture risk over 18 months.
- Category
- Clinical outcomes
02 · Primary record
Check the attached evidence
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.